土耳其的乙肝治疗：慢性乙肝患者乙肝表面抗原定量在长期随访中的价值——一项单中心研究
HBV Treatment in Turkey: The Value of Hepatitis B Surface Antigen Quantification of Chronic Hepatitis B Patients in the Long-term Follow-up-A Single-center Study.
作者信息
Ozkan Hasan
机构信息
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
出版信息
Euroasian J Hepatogastroenterol. 2017 Jan-Jun;7(1):82-83. doi: 10.5005/jp-journals-10018-1218. Epub 2017 May 5.
Abstract
Hepatitis B surface antigen (HBsAg) seems to have significant clinical implications to assess the prognosis of chronic hepatitis B (CHB). We assessed HBsAg levels serially in patients with CHB in a single center in Turkey. Ozkan H. HBV Treatment in Turkey: The Value of Hepatitis B Surface Antigen Quantification of Chronic Hepatitis B Patients in the Long-term Follow-up-A Single-center Study. Euroasian J Hepato-Gastroenterol 2017;7(1):82-83.
摘要
乙肝表面抗原（HBsAg）似乎对评估慢性乙型肝炎（CHB）的预后具有重要的临床意义。我们在土耳其的一个单中心对慢性乙型肝炎患者的HBsAg水平进行了连续评估。奥兹坎·H。土耳其的乙肝治疗：慢性乙型肝炎患者乙肝表面抗原定量在长期随访中的价值——一项单中心研究。《欧亚肝脏胃肠病学杂志》2017年；7(1):82 - 83。
相似文献
1
HBV Treatment in Turkey: The Value of Hepatitis B Surface Antigen Quantification of Chronic Hepatitis B Patients in the Long-term Follow-up-A Single-center Study.土耳其的乙肝治疗：慢性乙肝患者乙肝表面抗原定量在长期随访中的价值——一项单中心研究
Euroasian J Hepatogastroenterol. 2017 Jan-Jun;7(1):82-83. doi: 10.5005/jp-journals-10018-1218. Epub 2017 May 5.
2
Epidemiology of Chronic Hepatitis B in Turkey.土耳其慢性乙型肝炎的流行病学
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):73-74. doi: 10.5005/jp-journals-10018-1264. Epub 2018 May 1.
3
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.在 HBeAg 阴性 CHB 中对聚乙二醇干扰素 alfa-2a（40KD）的反应：HBsAg 血清水平的治疗中变化与 HBV 基因型有关。
J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.
4
Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.HBeAg 阴性慢性乙型肝炎病毒感染者的非活动和低病毒血症状态的长期结局：向 HBsAg 清除的良性过程。
Liver Int. 2017 Nov;37(11):1622-1631. doi: 10.1111/liv.13416. Epub 2017 Apr 18.
5
Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.基线 HBsAg 水平与持续正常丙氨酸氨基转移酶的 HBeAg 阴性慢性乙型肝炎感染中 HBsAg 丢失相关。
Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):310-316. doi: 10.1016/j.clinre.2018.10.017. Epub 2018 Dec 5.
6
Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.核苷类似物治疗 10 年后慢性乙型肝炎患者乙型肝炎表面抗原水平和乙型肝炎表面抗原血清学清除率的降低。
Hepatology. 2013 Sep;58(3):923-31. doi: 10.1002/hep.26376. Epub 2013 Jul 24.
7
Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.干扰素-γ诱导蛋白 10 kD 对慢性乙型肝炎患者聚乙二醇干扰素α治疗中乙型肝炎 e 抗原清除和乙型肝炎表面抗原下降的预测价值。
Antiviral Res. 2014 Mar;103:51-9. doi: 10.1016/j.antiviral.2014.01.001. Epub 2014 Jan 10.
8
Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?血清乙肝表面抗原（HBsAg）水平能否区分HBeAg阴性慢性乙型肝炎与非活动性携带状态？
Diagn Microbiol Infect Dis. 2015 Jun;82(2):114-9. doi: 10.1016/j.diagmicrobio.2015.02.005. Epub 2015 Feb 20.
9
Immunotherapy for Chronic Hepatitis B using HBsAg-based Vaccine Formulations: From Preventive Commercial Vaccines to Therapeutic Approach Julio Cesar Aguilar.使用基于乙肝表面抗原（HBsAg）的疫苗制剂治疗慢性乙型肝炎：从预防性商业疫苗到治疗方法 胡利奥·塞萨尔·阿吉拉尔
Euroasian J Hepatogastroenterol. 2014 Jul-Dec;4(2):92-97. doi: 10.5005/jp-journals-10018-1109. Epub 2014 Jul 28.
10
[Antiviral nucleotide-induced dynamic change of HBV DNA and HBsAg and significance of quarterly and annual quantitative measurements over 5-year follow-up of chronic hepatitis B patients].
Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):821-4. doi: 10.3760/cma.j.issn.1007-3418.2013.11.006.
本文引用的文献
1
Outcomes of laparoscopic feeding jejunostomy tube placement in 299 patients.299例患者腹腔镜下置入喂养空肠造口管的结果
Surg Endosc. 2016 Jan;30(1):126-31. doi: 10.1007/s00464-015-4171-4. Epub 2015 Mar 24.
2
Gastroenteric tube feeding: techniques, problems and solutions.胃肠管饲：技术、问题与解决方法
World J Gastroenterol. 2014 Jul 14;20(26):8505-24. doi: 10.3748/wjg.v20.i26.8505.
3
Jejunostomy tube feeding in patients undergoing esophagectomy.空肠造口管饲在食管癌切除术患者中的应用。
Can J Surg. 2013 Dec;56(6):409-14. doi: 10.1503/cjs.008612.
4
Feeding Tube-related Complications and Problems in Patients Receiving Long-term Home Enteral Nutrition.接受长期家庭肠内营养患者的饲管相关并发症及问题
Indian J Palliat Care. 2012 Jan;18(1):31-3. doi: 10.4103/0973-1075.97346.
5
A rare complication of jejunostomy tube: Enteral migration.
Turk J Gastroenterol. 2011 Feb;22(1):83-5. doi: 10.4318/tjg.2011.0162.
6
Enteral nutrition access devices.肠内营养通路装置。
Gastrointest Endosc. 2010 Aug;72(2):236-48. doi: 10.1016/j.gie.2010.02.008. Epub 2010 Jun 11.
7
Benefits versus risks: a prospective audit. Feeding jejunostomy during esophagectomy.益处与风险：一项前瞻性审计。食管癌切除术中的空肠造口喂养。
World J Surg. 2009 Jul;33(7):1432-8. doi: 10.1007/s00268-009-0019-1.
8
Enteral nutrition and oral nutrition supplements: a review of the economics literature.肠内营养与口服营养补充剂：经济学文献综述
JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):52-9. doi: 10.1177/014860710603000152.
9
Spontaneous antegrade enteral migration of feeding jejunostomy tube.空肠造口喂养管的自发性顺行性肠道内迁移。
Indian J Gastroenterol. 2005 Mar-Apr;24(2):74.
10
Feeding jejunostomy: is there enough evidence to justify its routine use?
Dig Surg. 2004;21(2):142-5. doi: 10.1159/000077454. Epub 2004 Mar 23.
Zotero 插件